X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (310) 310
hematology (217) 217
male (207) 207
female (200) 200
index medicus (198) 198
oncology (197) 197
middle aged (183) 183
adult (172) 172
aged (143) 143
antineoplastic combined chemotherapy protocols - therapeutic use (104) 104
treatment outcome (97) 97
chemotherapy (87) 87
rituximab (81) 81
prognosis (73) 73
disease-free survival (72) 72
lymphomas (72) 72
non-hodgkins-lymphoma (61) 61
aged, 80 and over (60) 60
retrospective studies (59) 59
antineoplastic agents - therapeutic use (51) 51
neoplasm staging (51) 51
cancer (50) 50
lymphoma (48) 48
therapy (48) 48
adolescent (47) 47
recurrence (46) 46
remission induction (46) 46
survival analysis (46) 46
classification (44) 44
lymphoma, non-hodgkin - drug therapy (41) 41
combined modality therapy (40) 40
cyclophosphamide - administration & dosage (40) 40
follicular lymphoma (40) 40
hemic and lymphatic diseases (40) 40
antineoplastic combined chemotherapy protocols - administration & dosage (38) 38
hematology, oncology and palliative medicine (36) 36
phase-ii (36) 36
vincristine - administration & dosage (36) 36
care and treatment (34) 34
disease (34) 34
young adult (33) 33
follow-up studies (32) 32
prednisone - administration & dosage (32) 32
brentuximab vedotin (31) 31
doxorubicin - administration & dosage (31) 31
survival (31) 31
b-cell lymphoma (27) 27
transplantation (27) 27
vidarabine - analogs & derivatives (27) 27
fludarabine (26) 26
lymphoma, large b-cell, diffuse - drug therapy (26) 26
patients (25) 25
trial (25) 25
antibodies, monoclonal - therapeutic use (24) 24
immune system diseases (24) 24
survival rate (24) 24
abridged index medicus (23) 23
analysis (23) 23
cyclophosphamide (23) 23
hodgkin disease - drug therapy (23) 23
antineoplastic agents (22) 22
bleomycin - administration & dosage (22) 22
cancer research (22) 22
non-hodgkin's lymphomas (22) 22
phase-ii trial (22) 22
time factors (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
drug administration schedule (21) 21
positron-emission-tomography (21) 21
response criteria (21) 21
salvage therapy (21) 21
antineoplastic agents - adverse effects (20) 20
high-dose chemotherapy (20) 20
hodgkin's disease (20) 20
malignant-lymphoma (20) 20
radiotherapy (20) 20
t cells (20) 20
chronic lymphocytic-leukemia (19) 19
hodgkin disease - pathology (19) 19
stem cell transplantation (19) 19
antibodies, monoclonal, murine-derived (18) 18
follow-up (18) 18
hematopoietic stem cell transplantation (18) 18
italy (18) 18
lymphoma, large b-cell, diffuse - pathology (18) 18
lymphoma, non-hodgkin - therapy (18) 18
macop-b (18) 18
radioimmunotherapy (18) 18
transplantation, autologous (18) 18
vidarabine - administration & dosage (18) 18
antibodies, monoclonal, murine-derived - administration & dosage (17) 17
antineoplastic combined chemotherapy protocols (17) 17
etoposide - administration & dosage (17) 17
leukemia (17) 17
lymphoma, large b-cell, diffuse - mortality (17) 17
lymphoma, non-hodgkin - mortality (17) 17
prednisone (17) 17
research (17) 17
antibodies, monoclonal - administration & dosage (16) 16
chop (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012, Volume 2012, pp. 426 - 432
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4779 - 4779
Abstract BACKGROUND: Axicabtagene ciloleucel (axi-cel) is a CD19-directed chimeric antigenic receptor (CAR) T-cell therapy which has been approved by FDA for... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5263 - 5263
To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1548 - 1548
Background: The prognosis is poor for most patients with lymphoma who do not respond to initial therapy, leaving an unmet need for effective therapies for this... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5252 - 5252
Background: Bruton tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling, which mediates B-cell proliferation, migration, and adhesion.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5322 - 5322
Abstract Background: Idelalisib (Zydelig®, IDELA), an oral agent, and copanlisib (Aliqopa®, COPA), an intravenous agent, are the only B-cell receptor pathway... 
Journal Article
Hematological Oncology, ISSN 0278-0232, 12/2017, Volume 35, Issue 4, pp. 909 - 910
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2920 - 2920
Abstract Older age (≥60 years) has consistently been identified as an independent adverse prognostic factor for Hodgkin lymphoma (HL) survival in... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4161 - 4161
Abstract Background: Bruton's tyrosine kinase (BTK) has a key role in B-cell receptor mediated pathways that are implicated in the pathogenesis of several... 
Journal Article
Hematological Oncology, ISSN 0278-0232, 12/2019, Volume 37, Issue 5, pp. 626 - 627
Follicular lymphoma is an indolent B cells proliferative disorder that represents approximately 35% of all non‐Hodgkin lymphomas. Although spontaneous... 
follicular lymphoma | spontaneous remission | immune response
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4135 - 4135
Background: In February 2017, CT-P10 became the first rituximab biosimilar to be approved in Europe for treatment of rheumatic diseases and specific blood... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2098 - 2098
Abstract Background: Veno-Occlusive Disease (VOD) or Sinusoidal Obstruction syndrome (SOS), is a rare but potentially life-threatening complication after... 
Journal Article
Blood, ISSN 0006-4971, 12/2017, Volume 130, Issue 25, pp. 2691 - 2692
In this issue of Blood, Pro et al have reported that it is possible to cure a subset of patients with relapsed or refractory (R/R) systemic anaplastic large... 
HODGKIN | BRENTUXIMAB VEDOTIN SGN-35 | EXPERIENCE | LARGE-CELL LYMPHOMA | HEMATOLOGY | NAMED PATIENT PROGRAM
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2241 - 2241
Abstract Introduction: DLBCL is an aggressive form of non-Hodgkin lymphoma (NHL) occurring more frequently in older patients (pts). Frontline treatment usually... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1716 - 1716
Abstract BACKGROUND: The objective of this study was to evaluate the effectiveness and safety of pixantrone as a rescue treatment for NHL patients in a real... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4167 - 4167
Abstract Introduction: Indolent NHL (iNHL) remains largely incurable, with the majority of patients (pts) eventually becoming refractory to standard therapies,... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.